168
Ifl
NGUEN et al.
(b) at fixed concentration of CHS solution in THF
(2% to the BTM mass; 0.1 mL, 1 mg/mL) and varying
concentration of porphyrin solution in THF (5 and
10% to the BTM mass).
Phosphate buffer (25 mL; pH 7.5, 10 mM) was
added to the mixture with a pipette upon intensive stirꢀ
ring, and the dispersion was stirred for 7 min at room
temperature. The solvent was removed on a rotary
evaporator at 35°C till the final volume reached
10 mL. Concentrated dispersions were centrifuged to
remove the sediment.
14
12
10
8
4
3
2
1
6
4
2
ACKNOWLEDGMENTS
0
500
550
600
650
700
750
800
The work was supported by the Russian Foundaꢀ
tion for basic Research (project no. 13ꢀ03ꢀ12046ꢀ
ofi_m) and the Ministry of Education and Science of
the Russian Federation.
Wavelength, nm
Fig. 5. Fluorescence spectra of porphyrin (
tration of 2% (0.01 mg/mL) in THF ( ), 2% in SANPs (
and after the addition of 0.4 M SDS to sample
porphyrin (control).
V
) at concenꢀ
),
, 0%
3
2
2. 1
REFERENCES
1. Balen, P., Martinet, M.C., Caron, G., Bouchard, G.,
Reist, M., Carrupt, P.ꢀA., Fruttero, R., Gasco, A., and
Testa, B., Med. Res. Rev., 2004, vol. 24, pp. 299–324.
2. Zhu, C., Liu, L., Yang, Q., Lu, F., and Wang, S., Chem.
Rev., 2012, vol. 112, no. 8, pp. 4687–4735.
8.96 (2 H, d, H3, H7,
H2, = 8.44 Hz), 8.14 (6 H, d, Ar H2,
7.48 (2 H, d, Ar H3, = 8.92), 7.35 (6 H, d, Ar H3,
8.25 Hz), 4.47 (2 H, m, ꢀOꢀCH2), 4.03 (2 H, m, ꢀOꢀ
CH2CH2), 3.83 (2 H, m, O(CH2)2OCH2), 3.75 (2 H,
m, CH3O(CH2)2OCH2ꢀ), 3.71 (2 H, m,
CH3OCH2CH2), 3.62 (2 H, m, CH3OꢀCH2), 3.39
(3 H, s, CH3O). 13C NMR (DMSOꢀd6: 158.35,
157.38, 135.47, 133.59, 131.83, 131.07, 130.52,
120.04, 119.23, 113.90, 112.95, 71.30, 70.01, 69.07,
J
= 4.77 Hz), 8. 22 (2 H, d, Ar
J
J
= 24.94 Hz),
J
J
=
3. Soini, A.E., Yashunsky, D.V., Meltola, N.J., and Ponoꢀ
marev, G.V., Luminescence, 2003, vol. 18, pp. 182–192.
4. Sezgin, Z., Yuksel, N., and Baykara, T., Int. J. Pharmaꢀ
ceutics, 2007, vol. 332, pp. 161–167.
5. Torchilin, V.P., Pharm. Res., 2007, vol. 24, pp. 1–16.
6. Kuruppuarachchi, M., Savoie, H., Lowry, A., Alonso, C.,
and Boyle, R.W., Mol. Pharmaceutics, 2011, vol. 8,
pp. 920–931.
7. Mojzisova, H., Bonneau, S., and Brault, D., Eur. Bioꢀ
phys. J., 2007, vol. 14, pp. 943–953.
67.39, 35.75, 30.75. MS,
lated 824.9 (C51H44N4O7). EAS (ethyl acetate), λmax
nm
ε × 10–3, М–1 cm–1): 418.0 (428), 515.8 (19.6),
m/z: 825.9 [M + H], calcuꢀ
,
(
552.6 (9.9), 592.4 (6.5), 650.6 (4.7).
8. Caminos, D.A. and Durantini, E.N., Bioorg. Med.
Chem., 2006, vol. 14, pp. 4253–4259.
Preparation of Spherical Amorphous Nanoparticles
from BTM and Porphyrins
9. SibrianꢀVazquez, M., Jensen, T.J., and Vicente, M.G.H.,
J. Photochem. Photobiol. B, 2007, vol. 86, pp. 9–21.
10. Vargas, A., Pegaz, B., Debefve, E., KonanꢀKouakou, Y.,
Lange, N., Ballini, J.ꢀP., Bergh, H., Gurny, R., and
Delie, F., Int. J. Pharmaceutics, 2004, vol. 286,
pp. 131–145.
The size of SANPs was estimated with turbidimetry
and dynamic light scattering. Zeta potential of the
nanoparticles was measured by electrophoretic light
scattering. Nanodispersion stability was evaluated by
the rate of the nanoparticle sedimentation upon cenꢀ
trifugation. Nanoparticle morphology was determined
by electron microscopy images obtained with negative
staining with 1% aqueous solution. In a 100ꢀmL
roundꢀbottom flask, solutions of BTM in THF (1 mL,
5 mg/mL) and porphyrin in THF (1 mg/mL) were
mixed. To stabilize the SANP membrane and study
the stability, cholesteryl hemisuccinate (CHS) in THF
(1 mg/mL) was added. Two series of experiments were
performed:
11. Ballut, S., NaudꢀMartin, D., Loock, B., and Maillard, P.,
Org. Chem., 2011, vol. 76, pp. 2010–2028.
12. Nishiyama, N., Stapert, H.R., Zhang, G.ꢀD., Takasu, D.,
Jiang, D.ꢀL., Nagano, T., Aida, T., and Kataoka, K.,
Bioconjugate Chem., 2003, vol. 14, pp. 58–66.
13. KramerꢀMarek, G., Serpa, C., Szurko, A., Widel, M.,
Sochanik, A., Snietura, M., Kus, P., Nunes, R.M.D.,
Arnaut, L.G., and Ratuszna, A., J. Photochem. Photoꢀ
biol. B, 2006, vol. 84, pp. 1–14.
14. Králová, J., Bríza, T., Moserová, I., Dolensky
Vašek, P., Pou ková, P., Kejik, Z., Kaplánek, R., Marꢀ
tásek, P., Dvo
ꢁ, B.,
c
r
ak, M., and Král, V., J. Med. Chem.
,
(a) at fixed concentration of porphyrin solution in
THF (2% to the BTM mass; 0.1 mL, 1 mg/mL) and
varying concentration of CHS solution in THF (0, 1,
and 5% to the BTM mass) and
2008, vol. 51, pp. 5964–5973.
15. Králová, J., Kejík, Z., Bríza, T., Pou
c
ková, P., Král, A.,
Martásek, P., and Král, V., J. Med. Chem., 2010, vol. 53,
pp. 128–138.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY Vol. 41
No. 2
2015